Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure

Soko Setoguchi Iwata, N. K. Choudhry, R. Levin, W. H. Shrank, W. C. Winkelmayer

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Although the complexity of treatment regimens for patients with heart failure (HF) has increased over time because of the increased availability of efficacious medications, little is known about temporal trends in adherence to treatment regimens in these patients. We assessed trends in adherence to angiotensin-system blockers (ABs), Β-blockers (BBs), and spironolactone (SL) for HF in Medicare beneficiaries enrolled in two statewide pharmacy benefit programs from 1995 to 2004. The proportion of days covered (PDC) (%) was assessed after the first dispensing among users of an AB, BB, or SL. Proportions of full adherence (PDC 80%) did not change over time for ABs (54% in both 1996 and 2003) but increased slightly for BBs (from 47% in 1996 to 57% in 2003) and SL (from 31% in 1996 to 42% in 2003). Black race and dialysis treatment predicted poor adherence to any medications. Adherence to BBs and SL increased modestly over time, but overall nonadherence remained high.

Original languageEnglish (US)
Pages (from-to)548-554
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume88
Issue number4
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Spironolactone
Angiotensins
Hospitalization
Heart Failure
N-(8-amino-1-carboxyoctyl)-alanyl-proline
Medicare
Dialysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{3daaaeb60c25453598e1f08cd906cb12,
title = "Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure",
abstract = "Although the complexity of treatment regimens for patients with heart failure (HF) has increased over time because of the increased availability of efficacious medications, little is known about temporal trends in adherence to treatment regimens in these patients. We assessed trends in adherence to angiotensin-system blockers (ABs), Β-blockers (BBs), and spironolactone (SL) for HF in Medicare beneficiaries enrolled in two statewide pharmacy benefit programs from 1995 to 2004. The proportion of days covered (PDC) ({\%}) was assessed after the first dispensing among users of an AB, BB, or SL. Proportions of full adherence (PDC 80{\%}) did not change over time for ABs (54{\%} in both 1996 and 2003) but increased slightly for BBs (from 47{\%} in 1996 to 57{\%} in 2003) and SL (from 31{\%} in 1996 to 42{\%} in 2003). Black race and dialysis treatment predicted poor adherence to any medications. Adherence to BBs and SL increased modestly over time, but overall nonadherence remained high.",
author = "{Setoguchi Iwata}, Soko and Choudhry, {N. K.} and R. Levin and Shrank, {W. H.} and Winkelmayer, {W. C.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1038/clpt.2010.139",
language = "English (US)",
volume = "88",
pages = "548--554",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure. / Setoguchi Iwata, Soko; Choudhry, N. K.; Levin, R.; Shrank, W. H.; Winkelmayer, W. C.

In: Clinical Pharmacology and Therapeutics, Vol. 88, No. 4, 01.10.2010, p. 548-554.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure

AU - Setoguchi Iwata, Soko

AU - Choudhry, N. K.

AU - Levin, R.

AU - Shrank, W. H.

AU - Winkelmayer, W. C.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Although the complexity of treatment regimens for patients with heart failure (HF) has increased over time because of the increased availability of efficacious medications, little is known about temporal trends in adherence to treatment regimens in these patients. We assessed trends in adherence to angiotensin-system blockers (ABs), Β-blockers (BBs), and spironolactone (SL) for HF in Medicare beneficiaries enrolled in two statewide pharmacy benefit programs from 1995 to 2004. The proportion of days covered (PDC) (%) was assessed after the first dispensing among users of an AB, BB, or SL. Proportions of full adherence (PDC 80%) did not change over time for ABs (54% in both 1996 and 2003) but increased slightly for BBs (from 47% in 1996 to 57% in 2003) and SL (from 31% in 1996 to 42% in 2003). Black race and dialysis treatment predicted poor adherence to any medications. Adherence to BBs and SL increased modestly over time, but overall nonadherence remained high.

AB - Although the complexity of treatment regimens for patients with heart failure (HF) has increased over time because of the increased availability of efficacious medications, little is known about temporal trends in adherence to treatment regimens in these patients. We assessed trends in adherence to angiotensin-system blockers (ABs), Β-blockers (BBs), and spironolactone (SL) for HF in Medicare beneficiaries enrolled in two statewide pharmacy benefit programs from 1995 to 2004. The proportion of days covered (PDC) (%) was assessed after the first dispensing among users of an AB, BB, or SL. Proportions of full adherence (PDC 80%) did not change over time for ABs (54% in both 1996 and 2003) but increased slightly for BBs (from 47% in 1996 to 57% in 2003) and SL (from 31% in 1996 to 42% in 2003). Black race and dialysis treatment predicted poor adherence to any medications. Adherence to BBs and SL increased modestly over time, but overall nonadherence remained high.

UR - http://www.scopus.com/inward/record.url?scp=77957017717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957017717&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.139

DO - 10.1038/clpt.2010.139

M3 - Article

VL - 88

SP - 548

EP - 554

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -